Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have been diagnosed with heart failure~* Women must be either postmenopausal or have been surgically sterilized at least 6 months ago~* Males must be willing to use an acceptable birth control method for 3 months after the last dose of study medication.~Exclusion Criteria:~* Patients must not have had an heart-assist device or heart transplant or be in imminent need of one~* Patients must not have had an ischemic attack within the last 6 months or a heart attack within the last month~* Patients must not have lung disease or congenital heart failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 86 Years
- Healthy Volunteers: f

Study Arms:
- Part 1 (Main Study) (Type: EXPERIMENTAL): 3 consecutive 1-hour infusions of JNJ-39588146 5, 15, or 30 ng/kg/min or matching placebo
- Part 2 (Extended Infusion Sub-Study) (Type: EXPERIMENTAL): 1 18-hr infusion of JNJ-39588146 of the highest tolerated dose from Part 1 of the study or matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).